Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login

New chikungunya vaccine

  • June 15, 2023
  • Posted by: OptimizeIAS Team
  • Category: DPN Topics
No Comments

 

 

New chikungunya vaccine

Subject: Science and technology

Section: Health

Concept:

  • A new clinical study shows promising results of a Phase III chikungunya vaccine trial, the first time the shot has been tested in humans.

Chikungunya

  • Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV) that causes fever and severe joint pain.
  • The disease was first recognized in 1952 during an outbreak in southern Tanzania.
  • It is a ribonucleic acid (RNA) virus that belongs to the alphavirus genus of the family Togaviridae.
  • The name “chikungunya” derives from a word in the Kimakonde language of southern Tanzania, meaning “to become contorted”, and describes the stooped appearance of sufferers with joint pain (arthralgia).
  • Chikungunya is transmitted to humans by the bites of infected female mosquitoes – Aedes aegypti and Aedes albopictus.

Treatment and vaccines

  • The clinical management includes addressing fever and joint pain.
  • There is no specific antiviral drug treatment for CHIKV infections.
  • There is no commercial vaccine available to protect against chikungunya virus infection.

Global scenario

  • Tropical regions currently see the highest rates of the virus, with Paraguay, Brazil, Bolivia and Thailand most affected.
  • Outbreaks have been ongoing in Congo, Sudan and Kenya since 2018, but cases have been relatively low.
  • However, a major 2013 outbreak of chikungunya in South America led to over 1 million infections in just a few months.
  • While death rates were low, around 52% of infected people experienced severe joint pain lasting months.
  • Studies suggest the disease caused the loss of 150,000 disability-adjusted life-years in 2014 alone.
  • The measurement represents the loss of the equivalent of one year of full health.

The new vaccine:

  • The vaccine contains a modified, live version of the chikungunya virus that can replicate in the body without causing severe illness.
  • Live vaccines closely mimic natural infections, triggering a robust immune response that provides long-lasting and broad protection.
  • Other live vaccines:
    • measles, mumps and rubella (MMR combined vaccine), smallpox and yellow fever are all live vaccines.
    • Risks associated with live vaccines:
    • Rare possibility of the weakened virus reverting to a more virulent form.
New chikungunya vaccine Science and tech

Recent Posts

  • Daily Prelims Notes 23 March 2025 March 23, 2025
  • Challenges in Uploading Voting Data March 23, 2025
  • Fertilizers Committee Warns Against Under-Funding of Nutrient Subsidy Schemes March 23, 2025
  • Tavasya: The Fourth Krivak-Class Stealth Frigate Launched March 23, 2025
  • Indo-French Naval Exercise Varuna 2024 March 23, 2025
  • No Mismatch Between Circulating Influenza Strains and Vaccine Strains March 23, 2025
  • South Cascade Glacier March 22, 2025
  • Made-in-India Web Browser March 22, 2025
  • Charting a route for IORA under India’s chairship March 22, 2025
  • Mar-a-Lago Accord and dollar devaluation March 22, 2025

About

If IAS is your destination, begin your journey with Optimize IAS.

Hi There, I am Santosh I have the unique distinction of clearing all 6 UPSC CSE Prelims with huge margins.

I mastered the art of clearing UPSC CSE Prelims and in the process devised an unbeatable strategy to ace Prelims which many students struggle to do.

Contact us

moc.saiezimitpo@tcatnoc

For More Details

Work with Us

Connect With Me

Course Portal
Search